Immunocore Holdings Limited: Immunocore Reports First Quarter 2021 Financial Results
Immunocore Holdings Limited: Immunocore Reports First Quarter 2021 Financial Results Launched includes $287 million in net proceeds from initial public offering and concurrent private placement in February 2021 Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced its results for the quarter ended March 31, 2021. Highlights for the quarter included the presentation of the Ph...
Source: finanznachrichten.de